United States-based law firm, Parker Waichman, has filed lawsuits on behalf of two below the knee amputees after the FDA concluded that Johnson & Johnson Co and Janssen Pharmaceuticals Inc's sodium-glucose co-transporter-2 (SGLT2) inhibitor diabetes treatment drugs Invokana, Invokamet, and Invokamet XR cause an increased risk of amputations of toes, feet and legs, it was reported yesterday.

The European Medicines Agency has also informed patients of potential increased risk of amputations for those taking any SGLT2 inhibitors.

Parker Waichman has filed the two lawsuits in New Jersey State Court - the Superior Court of New Jersey Law Division, Middlesex County, against Johnson & Johnson Co and Janssen Pharmaceuticals Inc. Both lawsuits contend that Johnson & Johnson and Janssen concealed, and continue to conceal, their knowledge of Invokana's unreasonably dangerous risks of lower limb amputations from consumers and the medical community.